SPECIFICITY STUDIES OF HIV AND HTLV PROTEASES

HIV 和 HTLV 蛋白酶的特异性研究

• 批准号: 6394931
• 负责人: Irene T Weber
• 金额: $ 3.97万
• 依托单位: GEORGIA STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-01 至 2002-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6394931
• 关键词: aspartic endopeptidases; drug resistance; human T cell lymphotropic virus type 1; human immunodeficiency virus 1; mutant; protease inhibitor; protein structure function; virus protein

Description: (Adapted from the Applicant's Abstract) The proposal's short-term aim is to eludicate the molecular basis for the action of resistant variants of Human Immunodeficiency Virus 1 (HIV-1) protease by comparing the structures and activities of selected mutants of HIV-1 and Rous sarcoma virus proteases. The specificity studies proposed will be: 1) to cover a broader set of oligopeptide substrates in order to more fully characterize the inhibitor-resistant HIV-1 protease mutants; and 2) promote new studies on the molecular basis for the specificity of the related human T-cell leukemia virus type 1 (HTLV-1) protease. The long-term aim is to predict new protease inhibitors and therapeutic strategies to overcome the problem of drug-resistance.

描述：（改编自申请人摘要）该提案的短期 目的是阐明耐药变体作用的分子基础 人类免疫缺陷病毒 1 (HIV-1) 蛋白酶的结构比较 HIV-1 和劳斯肉瘤病毒蛋白酶选定突变体的活性。这 提议的特异性研究将：1) 涵盖更广泛的寡肽 底物，以便更全面地表征抑制剂耐药性 HIV-1 蛋白酶突变体； 2）促进分子基础的新研究 相关人类 T 细胞白血病病毒 1 型 (HTLV-1) 的特异性 蛋白酶。长期目标是预测新的蛋白酶抑制剂和 克服耐药性问题的治疗策略。